Key result
TPly-BP significantly reduced in vivo calcification to approximately 30 µg/mL compared to 196 µg/mL for Glut-BP after 60 days of subcutaneous implantation in rats, while demonstrating good biocompatibility and antibacterial properties.
Why the study?
Bioprosthetic heart valve durability is limited by degeneration due to calcification, thrombus, endothelialization difficulty, and prosthetic valve endocarditis.
Absolute Event Rate: 30% vs 196%
Modification of glutaraldehyde-crosslinked bovine pericardium with tannic acid and polylysine nanoaggregates significantly reduces in vivo calcification and improves biocompatibility, offering a promising material for durable bioprosthetic heart valves.
Hypothesis-generating for bioprosthetic materials; leaves open translation to human valve durability.
Glutaraldehyde (Glut)-crosslinked porcine pericardium and bovine pericardium are mainly consisted of collagen and widely used for the preparation of heterogenous bioprosthetic heart valves (BHV), which play an important role in the replacement therapy of severe valvular heart disease, while their durability is limited by degeneration due to calcification, thrombus, endothelialization difficulty and prosthetic valve endocarditis. Herein, we develop a novel BHV, namely, TPly-BP, based on natural tannic acid and polylysine to improve the durability of Glut crosslinked bovine pericardium (Glut-BP). Impressively, tannic acid and polylysine could form nanoaggregates via multiple hydrogen bonds and covalent bonds, and the introduction of nanoaggregates not only improved the mechanical properties and collagen stability but also endowed TPly-BP with good biocompatibility and hemocompatibility. Compared to Glut-BP, TPly-BP showed significantly reduced cytotoxicity, improved endothelial cell adhesion, a low hemolysis ratio and obviously reduced platelet adhesion. Importantly, TPly-BP exhibited great antibacterial and in vivo anti-calcification ability, which was expected to improve the in vivo durability of BHVs. These results suggested that TPly-BP would be a potential candidate for BHV.
No takes yet. Share an insight, caveat, or question.
Li et al. (2022) studied Valvular heart disease. TPly-BP (Tannic acid and polylysine modified glutaraldehyde-crosslinked bovine pericardium) vs. Glut-BP (Glutaraldehyde-crosslinked bovine pericardium) was evaluated on Calcium content after 60 days of subcutaneous implantation. TPly-BP significantly reduced in vivo calcification to approximately 30 µg/mL compared to 196 µg/mL for Glut-BP after 60 days of subcutaneous implantation in rats, while demonstrating good biocompatibility and antibacterial properties.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: